MiniMed® Connect Mobile Accessory for Android Now Available from Medtronic
October 24 2016 - 9:00AM
MiniMed Connect
Mobile Accessory Provides Easier and Better Access to Pump and CGM
Data, Helping Optimize Therapy for Improved Glycemic
Patterns
DUBLIN - October 24, 2016 -
Medtronic plc (NYSE:MDT), the global leader in medical technology,
today announced U.S. commercial availability of the Android(TM)
operating system version of the MiniMed Connect mobile accessory,
the first and only product enabling people with diabetes to see
their real-time glucose level on Android mobile devices.
The MiniMed Connect app, which was originally
launched on iOS in September 2015, helps people with diabetes see
how they're doing right on their phone by providing convenient
access to their insulin pump and CGM (continuous glucose
monitoring) data in an easy-to-use smartphone application.
The MiniMed Connect app also allows care partners to better
participate in diabetes care with real-time access to glucose and
insulin data on any Internet-connected mobile device or PC and
therapy alerts via text message. In addition, the MiniMed
Connect app allows healthcare providers to more efficiently access
data for therapy optimization through daily uploads of insulin and
CGM information into CareLink® therapy management software.
The MiniMed Connect app enables people with
diabetes and their healthcare providers to better optimize therapy,
leading to improved glycemic patterns. In a retrospective analysis
of CareLink data1 on nearly
2,800 patients, use of the MiniMed Connect app resulted in:
-
Two fewer severe low blood sugar events (<50
mg/dl for more than 20 minutes) per year
-
Forty-one fewer severe high blood sugar events
(>300 mg/dl for more than 20 minutes) per year
-
66 percent of patients stayed in range more
often
"In addition to greater convenience, our recent
data shows that with easier and better access to their data, the
MiniMed Connect app helps patients reduce high and low sugar
events, and keep their sugar within range more often," said Annette
Brüls, president, Diabetes Service and Solutions business at
Medtronic. "Making the MiniMed Connect app available for Android
users, their loved ones and their care partners propels us forward
in our goal to meet both the diabetes management and lifestyle
needs of people with diabetes so they can live with greater freedom
and better health."
"For individuals with diabetes, the need to
constantly monitor sugar levels can be cumbersome and far from
discreet," said Dr. David Rhew, chief medical officer and head of
healthcare and fitness at Samsung. "Working with Medtronic, we are
harnessing the power of industry leading mobile technology to make
diabetes management less stressful and more seamless for the
millions of Americans living with the condition. Samsung is
thrilled to partner with Medtronic to launch the first-of-its-kind
MiniMed Connect application on Android, which has been tested and
approved for use on many of Samsung's flagship smartphones
including the Samsung Galaxy S7 and Galaxy S7 Edge."
The MiniMed Connect app is compatible with both
the MiniMed® 530G system and the MiniMed® Revel(TM) system,
providing greater convenience for people with diabetes, greater
peace of mind for their care partners, and more convenient access
to diabetes data for healthcare teams.
- People with diabetes can discreetly view their
diabetes information on a smartphone application.
- The MiniMed Connect app allows care partners to
view and monitor this diabetes information via CareLink Personal
software, delivering preset text notifications to care partners
when the person with diabetes experiences sugar levels that go too
high or too low or when an alarm on the pump isn't cleared.
- With patient permission, and as arranged with
their healthcare providers, there can be convenient access to
diabetes data in the CareLink reports.
- The MiniMed Connect app for Android will work on
a wide variety of Android devices including Samsung Galaxy S7 and
Galaxy S7 Edge which are among best-selling smartphones in the
world for 20162.
Medtronic's vision is to transform diabetes care,
together for greater freedom and better health. This vision is
centered around a deep-rooted belief in delivering solutions so
that people with diabetes can live their exceptional lives. The
MiniMed Connect app achieves this objective and is also a further
demonstration of how Medtronic is moving beyond insulin pumps and
CGM devices and integrating leading consumer technologies, data and
informatics to enable better therapy decision-making and care.
The MiniMed Connect mobile accessory, now
available for Android devices, is the first product to enable
people with diabetes to discreetly and conveniently view their
insulin pump and CGM information on a smartphone.
Click the thumbnail above for a larger image.
About the Diabetes Group at
Medtronic (www.medtronicdiabetes.com)
Medtronic is working together with the global community to change
the way people manage diabetes. The company aims to transform
diabetes care by expanding access, integrating care and improving
outcomes, so people living with diabetes can enjoy greater freedom
and better health.
About Medtronic
Medtronic plc (www.medtronic.com), headquartered in Dublin,
Ireland, is among the world's largest medical technology, services
and solutions companies - alleviating pain, restoring health and
extending life for millions of people around the world. Medtronic
employs more than 88,000 people worldwide, serving physicians,
hospitals and patients in more than 160 countries. The company is
focused on collaborating with stakeholders around the world to take
healthcare Further, Together.
Any forward-looking statements
are subject to risks and uncertainties such as those described in
Medtronic's periodic reports on file with the Securities and
Exchange Commission. Actual results may differ materially from
anticipated results.
-end-
1 Retrospective
analysis of data uploaded to CareLink database for 2,794 patients
using the MiniMed Connect device and app for at least 60 days,
collected from September 2015 to May 2016. Data is compared to
prior 60 days of CareLink data before using MiniMed Connect app.
All data based on sensor glucose measurements.
Contacts:
Pamela Reese
Public Relations
+1-818-576-3398
Ryan Weispfenning
Investor Relations
+1-763-505-4626
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Medtronic plc via Globenewswire
Medtronic (NYSE:MDT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Medtronic (NYSE:MDT)
Historical Stock Chart
From Apr 2023 to Apr 2024